The Potential of Antiviral Peptides as COVID-19 Therapeutics

Mahendran, Arun Suria Karnan; Lim, Yin Sze; Fang, Chee‐Mun; Loh, Hwei-San; Le, Cheng Foh

doi:10.3389/fphar.2020.575444

Cited by 68 publications

(75 citation statements)

References 42 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the COVID-19 pandemic was announced, various options have been proposed to combat the infection. Recently, reviews have appeared that draw attention to the prospects for the development and use of antiviral peptides in the therapy of SARS-CoV-2, SARS-CoV-1, MERS-CoV and other respiratory viruses [ 281 ]. In particular, there was a point of view that synthetic or natural AMPs can be used to reduce the viral load on cells by blocking the contacts of the virus with receptors on the cell surface [ 22 ].…”

Section: Prediction and Development Of New Ampsmentioning

confidence: 99%

Antimicrobial and Amyloidogenic Activity of Peptides. Can Antimicrobial Peptides Be Used against SARS-CoV-2?

Kurpe

Grishin

Surin

et al. 2020

IJMS

View full text Add to dashboard Cite

At present, much attention is paid to the use of antimicrobial peptides (AMPs) of natural and artificial origin to combat pathogens. AMPs have several points that determine their biological activity. We analyzed the structural properties of AMPs, as well as described their mechanism of action and impact on pathogenic bacteria and viruses. Recently published data on the development of new AMP drugs based on a combination of molecular design and genetic engineering approaches are presented. In this article, we have focused on information on the amyloidogenic properties of AMP. This review examines AMP development strategies from the perspective of the current high prevalence of antibiotic-resistant bacteria, and the potential prospects and challenges of using AMPs against infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

show abstract

Section: Prediction and Development Of New Ampsmentioning

confidence: 99%

Antimicrobial and Amyloidogenic Activity of Peptides. Can Antimicrobial Peptides Be Used against SARS-CoV-2?

Kurpe

Grishin

Surin

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…However, reports show COVID-19 vaccines are not going to be a silver bullet for the immunization of a community. And, for the long-run alternatives to the traditional therapeutics would be necessary as before [47,48].…”

Section: Resultsmentioning

confidence: 99%

A novel peptide analogue of spike glycoprotein shows antiviral properties against SARS-CoV-2: An in silico approach through molecular docking, molecular dynamics simulation and MM-PB/GBSA calculations

Dutta

Elmezayen

Al-Obaidi

et al. 2020

Preprint

View full text Add to dashboard Cite

At the very beginning of the new decade, the COVID-19 pandemic has badly hit modern human societies. SARS-CoV-2, the causative agent of COVID-19 carries dozens of new mutations in its genome. Herein, we made an effort to find new antiviral peptides (AVPs) against SARS-CoV-2. Gladly, with the help of Machine Learning algorithms, and Supported Vector Machine, we have invented three new AVPs against the SARS-CoV-2. Antiviral peptides viz., Seq12, Seq12m, and Seq13m can block the receptor binding domain (RBD) of the SARS-CoV-2, necessary for communication with the angiotensin-converting enzyme 2 (ACE2). In addition, these AVPs retain their antiviral properties, even after the insertion of dozens of new mutations (Rosetta, and FoldX based) in the RBD. Further, Seq12, and Seq12m showed negligible cytotoxicity. Besides, the binding free energy calculated using MM-PB/GBSA method is also in agreement with the molecular docking studies performed using HADDOCK. Furthermore, the molecular interactions between AVPs and the viral membrane protein (M) also showed a thermodynamically favorable interaction, suggesting it could eventually inhibit the viral re-packaging process. In conclusion, this study suggests AVPs viz., Seq12, Seq12m, and Seq13m embrace importance as a potential anti-SARS-CoV-2 therapeutic. These AVPs could also aid virus diagnostic tools in the future.

show abstract

“…More than 60 peptide drugs have been approved in the USA and other countries [41]. Mahendran et al illustrated different antiviral peptides that can be used for the treatment targeting the S protein [42]. VanPatten et al described the peptides and peptidomimetics for the therapeutic treatment targeting the S protein [43].…”

Section: Designing Of Viral Entry Inhibitors Using Protein Drug Targetsmentioning

confidence: 99%

SARS-CoV-2 protein drug targets landscape: a potential pharmacological insight view for the new drug development

Chakraborty

Bhattacharya

Mallick

et al. 2021

Expert Review of Clinical Pharmacology

View full text Add to dashboard Cite

Introduction: Protein drug targets play a significant choice in different stages of the drug discovery process. There is an urgent need to understand the drug discovery approaches and protein drug targets (PDT) of SARS-CoV-2, with structural insights for the development of SARS-CoV-2 drugs through targeted therapeutic approach. Areas covered: We have described the protein as a drug target class and also discussed various drug discovery approaches for SARS-CoV-2 involving the protein drug targets such as drug repurposing study, designing of viral entry inhibitors, viral replication inhibitors, and different enzymes of the virus. We have performed comprehensive literature search from the popular databases such as PubMed Google scholar, Web of Science, and Scopus. Finally, we have illustrated the structural landscape of different significant viral proteins (3 CLpro or Mpro, PLpro, RdRp, helicase, S protein) and host proteins as drug targets (cathepsin L, furin, TMPRSS2, ACE2). Expert opinion: The structural landscape of PDT with their binding pockets, and significant residues involved in binding has been discussed further to better understand the PDT and the structure-based drug discovery for SARS-CoV-2. This attempt will increase more therapeutic options, and combination therapies with a multi-target strategy.

show abstract

The Potential of Antiviral Peptides as COVID-19 Therapeutics

Cited by 68 publications

References 42 publications

Antimicrobial and Amyloidogenic Activity of Peptides. Can Antimicrobial Peptides Be Used against SARS-CoV-2?

Antimicrobial and Amyloidogenic Activity of Peptides. Can Antimicrobial Peptides Be Used against SARS-CoV-2?

A novel peptide analogue of spike glycoprotein shows antiviral properties against SARS-CoV-2: An in silico approach through molecular docking, molecular dynamics simulation and MM-PB/GBSA calculations

SARS-CoV-2 protein drug targets landscape: a potential pharmacological insight view for the new drug development

Contact Info

Product

Resources

About